ArticlePharmaceuticals (Basel, Switzerland)2025
Correction: Malebari et al. Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4.
Azizah M Malebari, Shu Wang, Thomas F Greene, Niamh M O'Boyle, Darren Fayne, Mohemmed Faraz Khan, Seema M Nathwani, Brendan Twamley, Thomas McCabe, Daniela M Zisterer and 1 more
Abstract readPublished Erratum
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors.
Azizah M MalebariDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Shu WangSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Dublin 2, DO2R590 Dublin, Ireland.
Thomas F GreeneSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Dublin 2, DO2R590 Dublin, Ireland.
Niamh M O'BoyleSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Dublin 2, DO2R590 Dublin, Ireland.ORCID 0000-0001-5660-4944 Darren FayneMolecular Design Group, School of Biochemistry and Immunology, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Dublin 2, DO2R590 Dublin, Ireland.ORCID 0000-0003-2417-5406 Mohemmed Faraz KhanMolecular Design Group, School of Biochemistry and Immunology, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Dublin 2, DO2R590 Dublin, Ireland.ORCID 0000-0003-3846-1577 Seema M NathwaniSchool of Biochemistry and Immunology, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Dublin 2, DO2R590 Dublin, Ireland.
Brendan TwamleySchool of Chemistry, Trinity College Dublin, Dublin 2, DO2R590 Dublin, Ireland.
Thomas McCabeSchool of Chemistry, Trinity College Dublin, Dublin 2, DO2R590 Dublin, Ireland.
Daniela M ZistererSchool of Biochemistry and Immunology, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Dublin 2, DO2R590 Dublin, Ireland.ORCID 0000-0001-5005-1023 Mary J MeeganSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, Dublin 2, DO2R590 Dublin, Ireland.ORCID 0000-0002-8930-5753 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
In the original publication [...].
Identifiers
PMID40872633
PMCPMC12389276
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390